Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.690
-0.040 (-2.31%)
At close: Aug 1, 2025, 4:00 PM
1.670
-0.020 (-1.18%)
After-hours: Aug 1, 2025, 6:47 PM EDT
Augmedix Stock Forecast
Stock Price Forecast
The 2 analysts that cover Augmedix stock have a consensus rating of "Strong Buy" and an average price target of $5.00, which forecasts a 195.86% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $6.00.
Price Target: $5.00 (+195.86%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 9, 2025.
Analyst Ratings
The average analyst rating for Augmedix stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +255.03% | Jun 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +136.69% | Apr 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +136.69% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +136.69% | Dec 4, 2024 |
| Needham | Needham | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +136.69% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
161.71M
from 144.29M
Increased by 12.08%
Revenue Next Year
182.04M
from 161.71M
Increased by 12.57%
EPS This Year
-0.02
from -0.09
EPS Next Year
0.07
from -0.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 167.9M | 192.9M | 232.9M | ||
| Avg | 161.7M | 182.0M | 212.1M | ||
| Low | 153.2M | 169.8M | 196.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.4% | 19.3% | 27.9% | ||
| Avg | 12.1% | 12.6% | 16.5% | ||
| Low | 6.2% | 5.0% | 7.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.01 | 0.12 | 0.27 | ||
| Avg | -0.02 | 0.07 | 0.21 | ||
| Low | -0.06 | 0.04 | 0.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 301.5% | ||
| Avg | - | - | 210.0% | ||
| Low | - | - | 116.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.